Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

• DOI: 10.1016/j.annonc.2022.02.007
• Publication Date: 2022-03-17T00:16:56Z
• Authors: D. Gale; K. Heider; A. Ruiz-Valdepenas; S. Hackinger; M. Perry; G. Marsico; V. Rundell; J. Wulff; G. Sharma; H. Knock; J. Castedo; W. Cooper; H. Zhao; C.G. Smith; S. Garg; S. Anand; K. Howarth; D. Gilligan; S.V. Harden; D.M. Rassl; R.C. Rintoul; N. Rosenfeld
• Keywords: Chemoradiotherapy

Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment curative intent holds promise to identify at risk relapse. New methods can detect circulating tumour DNA (ctDNA) plasma fractional concentrations as low a few parts per million, and clinical evidence is required inform their use.